Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Midterms trans sports, abortion props, Theranos: Morning Rounds (opens in a new tab)

statnews.com · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

3 key claims are not backed by the study. One other point was not covered by the paper.

  • 1 supported
  • 3 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Three claims aren't supported by the study. One of five checks out. One claim the study doesn't address.

  • 1 supported
  • 3 not supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedState ballot measures on contentious health care issues like transgender rights and abortion access will provide a concrete view of how voters across the U.S. regard these matters two years into the Trump administration.View evidenceHide evidence

Why this verdict

The supplied paper profile is about model-based projections of childhood hepatitis B vaccination policy options. It contains no evidence about state ballot measures, transgender rights, abortion access, or voter attitudes.

Claim 2 of 5Not supportedIn 2025, nearly half of American women ages 40 to 60 reported at least one symptom of menopause, and 15.6% of those reporting symptoms were taking prescription medications to manage them, according to CDC data.View evidenceHide evidence

As stated15.6%

Why this verdict

The supplied paper profile does not address menopause symptoms, prescription medication use for menopause, CDC menopause data, or women ages 40 to 60.

Claim 3 of 5Not supportedA new study from the University of Pennsylvania’s Annenberg Public Policy Center found that broader perceptions of science and scientists are much more strongly correlated to vaccine uptake than partisan differences, except for the Covid-19 vaccine.View evidenceHide evidence

Why this verdict

The supplied paper profile does not address vaccine hesitancy surveys, perceptions of science or scientists, partisanship, Covid-19 vaccine attitudes, or the University of Pennsylvania Annenberg Public Policy Center.

Claim 4 of 5Not coveredExperts at Massachusetts General Hospital and Harvard Medical School built a model comparing the birth dose with vaccination at two months and with a shared decision-making conversation at two months.View evidenceHide evidence

Why this verdict

The model comparison itself is supported: the paper used a Markov cohort state-transition model comparing universal birth-dose vaccination, deferred 2-month vaccination, and vaccination through shared decision-making. However, the supplied abstract-level profile does not provide author affiliations, so the claim that the experts were at Massachusetts General Hospital and Harvard Medical School is not verifiable from this profile depth.

1

Study evidence

In the base-case Markov cohort model, the deferred (2-month) vaccination strategy projected 303 childhood chronic HBV infections (95% UI, 155 to 610) versus 255 (95% UI, 130 to 530) under universal birth-dose.19% increase (deferred vs universal birth-dose)

“DESIGN: Markov cohort state transition model of perinatal and childhood HBV infection.”
Claim 5 of 5SupportedNew research suggests the Trump administration’s changes to the hepatitis B vaccine schedule could lead to a jump in chronic hepatitis B infections among children.View evidenceHide evidence

As stated19% or 83% increase in chronic infections acquired by age 20, depending on scenario

Why this verdict

The abstract-level profile supports the core scientific claim: a Markov cohort model projected higher childhood chronic HBV infections if vaccination is deferred to 2 months or handled through shared decision-making versus a universal birth dose, with base-case increases of 19% and 83%. The story’s hedged wording ('could lead') and caveat that these are model projections align with the paper. The supplied profile does not independently verify the political attribution to the Trump administration, but the modeled policy-change claim is supported.

1

Study evidence

In the base-case Markov cohort model, the deferred (2-month) vaccination strategy projected 303 childhood chronic HBV infections (95% UI, 155 to 610) versus 255 (95% UI, 130 to 530) under universal birth-dose.19% increase (deferred vs universal birth-dose)

“DESIGN: Markov cohort state transition model of perinatal and childhood HBV infection.”
2

Study evidence

Probabilistic sensitivity analysis produced 95% uncertainty intervals for projected childhood chronic HBV infections under each vaccination strategy.Universal birth-dose: 255 (95% UI, 130 to 530); Deferred: 303 (95% UI, 155 to 610); Shared decision-making: 467 (95% UI, 209 to 1032).

“95% uncertainty intervals (UIs) derived from probabilistic sensitivity analysis.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Secondary outcome: projected HBV susceptibility at year 20 was substantially higher under deferred vaccination and shared decision-making, with 474,000 and 1,806,000 susceptible people versus 232,000 under universal birth dose.

    The story focuses on projected chronic infections and does not mention the paper’s distinct susceptibility-at-year-20 outcome.

    From Markov cohort state-transition model

  • Uncertainty quantification: the paper used probabilistic sensitivity analysis and reported 95% uncertainty intervals for projected chronic infection counts.

    The story notes that the results are model-based but does not report the uncertainty intervals or discuss probabilistic sensitivity analysis.

    From Probabilistic sensitivity analysis and scenario analysis

  • Sensitivity/scenario analysis: under lower vaccine coverage, higher maternal HBV prevalence, and higher horizontal infection risk, projected infections were much larger: 1700 for deferred vaccination and 2192 for shared decision-making.

    The story does not mention the adverse-parameter sensitivity scenario or its larger projected infection counts.

    From Probabilistic sensitivity analysis and scenario analysis

  • Key limitations: projections depend on input values and structural assumptions, and the authors specifically note uncertainty in horizontal HBV infection risk.

    Although the story acknowledges the projections are model-based, it does not mention the specific interpretation-relevant limitation about horizontal HBV infection risk or the dependence on model input assumptions.

    From Markov cohort state-transition model; Probabilistic sensitivity analysis and scenario analysis

3 things the story did carry across
  • Primary design and scope: a Markov cohort state-transition decision model of perinatal and childhood HBV infection in a one-year U.S.-born infant cohort of 3.6 million, comparing universal birth dose, deferred 2-month vaccination, and shared decision-making over 20 years.
  • Base-case projected chronic HBV infections were higher under alternative policies: 303 under deferred vaccination versus 255 under universal birth dose, a 19% increase; and 467 under shared decision-making versus 255, an 83% increase.
  • The findings are model-based projections, not empirical observed infection outcomes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

in silico

1Lead resultin silicoProject the impact of alternative 2026 U.S. childhood hepatitis B vaccination policy options (universal birth dose vs deferred to 2 months vs shared decision making) on chronic HBV infections over 20 years in a U.S. birth cohort.Markov cohort state-transition modelExpand

In plain English

Markov cohort state-transition model projecting chronic hepatitis B infections over 20 years in a single U.S. birth cohort (n = 3.6 million) under three 2026 childhood vaccination policy options (universal birth-dose, deferred 2-month, shared decision making).

Key findings

  • In the base-case Markov cohort model, the deferred (2-month) vaccination strategy projected 303 childhood chronic HBV infections (95% UI, 155 to 610) versus 255 (95% UI, 130 to 530) under universal birth-dose.19% increase (deferred vs universal birth-dose)
  • In the base-case model, the shared decision-making strategy projected 467 childhood chronic HBV infections (95% UI, 209 to 1032) versus 255 (95% UI, 130 to 530) under universal birth-dose.83% increase (shared decision-making vs universal birth-dose)
“DESIGN: Markov cohort state transition model of perinatal and childhood HBV infection.”
What this piece can’t prove
  • Uncertainty in horizontal HBV infection risk noted by authors.
  • Projections are model-based and depend on input parameter values (e.g., maternal prevalence, vaccine uptake) and structural assumptions of the Markov model.
2in silicoQuantify how alternative vaccination policies affect the number of HBV-susceptible individuals at 20 years (population susceptibility entering adulthood).Markov cohort state-transition modelExpand

In plain English

Model-based projection of number of HBV-susceptible individuals at year 20 for a 2026 U.S.-born infant cohort (n = 3.6 million) under three childhood hepatitis B vaccination strategies: universal birth-dose vaccination, deferred (2-month) vaccination, and vaccination via shared decision making. The model estimates substantially higher counts of susceptibles at year 20 for the deferred and shared decision-making strategies versus universal birth dose.

Key findings

  • Counts of HBV-susceptible individuals at year 20 differ by vaccination strategy: universal birth-dose = 232,000; deferred = 474,000; shared decision making = 1,806,000 (cohort n = 3.6 million).Deferred vs universal: +242,000 susceptible; Shared decision making vs universal: +1,574,000 susceptible.
“OUTCOME MEASURES: Numbers with chronic HBV infection and susceptibility to HBV”
What this piece can’t prove
  • Abstract notes uncertainty in horizontal HBV infection risk, which affects modeled outcomes.

2 further details could not be confirmed from the summary.

3in silicoCharacterize uncertainty and robustness of projections via probabilistic sensitivity analysis and scenario/sensitivity analyses (e.g., lower coverage, higher maternal HBV prevalence, higher horizontal infection risk).Probabilistic sensitivity analysis and scenario analysisExpand

In plain English

The study used probabilistic sensitivity analysis (PSA) to quantify parameter uncertainty (reporting 95% uncertainty intervals) and conducted scenario/sensitivity analyses (including a scenario with lower vaccine coverage, higher maternal HBV prevalence, and higher horizontal transmission risk) to assess robustness of model projections for childhood chronic HBV infections under alternative vaccination policies. PSA-derived intervals and scenario results show substantially larger projected infections under deferred or shared-decision strategies versus a universal birth-dose strategy; the authors highlight uncertainty in horizontal transmission risk as a key limitation.

Key findings

  • Probabilistic sensitivity analysis produced 95% uncertainty intervals for projected childhood chronic HBV infections under each vaccination strategy.Universal birth-dose: 255 (95% UI, 130 to 530); Deferred: 303 (95% UI, 155 to 610); Shared decision-making: 467 (95% UI, 209 to 1032).
  • A sensitivity scenario combining lower vaccine coverage and higher maternal prevalence plus increased horizontal transmission risk yielded substantially higher projected infections.Deferred strategy: 1700 infections; Shared decision-making strategy: 2192 infections (scenario values reported in abstract).
“95% uncertainty intervals (UIs) derived from probabilistic sensitivity analysis.”
What this piece can’t prove
  • Uncertainty in horizontal HBV infection risk explicitly noted by the authors.
  • Abstract does not provide details of PSA implementation (parameter distributions, number of simulation draws, correlation structure) needed to fully assess robustness of uncertainty quantification.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 16 candidate papers

Candidate

Assessing the burden of hepatitis B in South Africa, predicting disease prevalence and modelling the impact of hepatitis B birth dose vaccination

Crossref

Source (opens in a new tab)

And 10 more candidates considered.